INOVIO Form 4 — KIES PETER (March 11, 2022)
Summary
Peter Kies, CFO of INOVIO PHARMACEUTICALS, INC. [ INO ], reports that 59,737 Restricted Stock Units converted to Common Stock on 03/11/2022 under a 179,211-unit award vesting in three equal parts on March 11 of 2021, 2022 and 2023. The issuer withheld 31,410 shares at $ 3.22 for tax withholding, leaving 179,284 shares owned directly; 4,500 shares are listed as owned by spouse. After the conversion 59,737 units remain. The form is signed Peter Kies, 03/14/2022.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“INOVIO Form 4 — KIES PETER (March 11, 2022).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-ino-4-filed2022-03-14-0001055726-22-000019-77f4fd508d/
, SHA-256 b159a30edac13973c006acd50b7acaac29bde285c3c8e0c8cfa80921ecf560bb.Full text
SEC Form 4 FORM 4 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 | OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB APPROVAL | OMB Number: 3235-0287 Estimated average burden hours per response: 0.5 | OMB Number: | 3235-0287 | Estimated average burden | hours per response: | 0.5 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). 1. Name and Address of Reporting Person * KIES PETER (Last) (First) (Middle) C/O INOVIO PHARMACEUTICALS, INC. 6769 MESA RIDGE ROAD (Street) SAN DIEGO CA 92121 (City) (State) (Zip) | KIES PETER | (Last) | (First) | (Middle) | C/O INOVIO PHARMACEUTICALS, INC. | 6769 MESA RIDGE ROAD | SAN DIEGO | CA | 92121 | (City) | (State) | (Zip) | 2. Issuer Name and Ticker or Trading Symbol INOVIO PHARMACEUTICALS, INC. [ INO ] | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) CFO | Director | 10% Owner | X | Officer (give title below) | Other (specify below) | CFO 3. Date of Earliest Transaction (Month/Day/Year) 03/11/2022 4. If Amendment, Date of Original Filed (Month/Day/Year) | 6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person | X | Form filed by One Reporting Person | Form filed by More than One Reporting Person Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | Amount | (A) or (D) | Price Common Stock | 03/11/2022 | M | 59,737 | A | (1) | 210,694 | D Common Stock | 03/11/2022 | F (2) | 31,410 | D | $ 3.22 | 179,284 | D Common Stock | 4,500 | I | By Spouse Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares Restricted Stock Unit | (1) | 03/11/2022 | M | 59,737 | (1) | (1) | Common Stock | 59,737 | $ 0 (1) | 59,737 | D Explanation of Responses: 1. Each restricted stock unit represents a contingent right to receive one share of common stock. The vesting schedule for the 179,211 restricted stock units is as follows: 59,737 shares vested on March 11, 2021; 59,737 shares vested on March 11, 2022; 59,737 shares will vest on March 11, 2023. Vested restricted stock units can be settled in shares of common stock, cash or a combination of both. 2. The transaction reported represents the withholding of shares by the issuer to satisfy the reporting person's tax withholding obligations in connection with the vesting and settlement of the restricted stock unit award reported in footnote (1) herein. Remarks: Peter Kies | 03/14/2022 ** Signature of Reporting Person | Date Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v). ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
File and source
- File
- SEC_INO_4_filed2022-03-14_0001055726-22-000019.xml
- Size
- 17,739 bytes
- SHA-256
- b159a30edac13973c006acd50b7acaac29bde285c3c8e0c8cfa80921ecf560bb
- Original
- www.sec.gov